CN101120969A - Medicine for treating diabetes and its complications and preparing method thereof - Google Patents
Medicine for treating diabetes and its complications and preparing method thereof Download PDFInfo
- Publication number
- CN101120969A CN101120969A CNA2006101043298A CN200610104329A CN101120969A CN 101120969 A CN101120969 A CN 101120969A CN A2006101043298 A CNA2006101043298 A CN A2006101043298A CN 200610104329 A CN200610104329 A CN 200610104329A CN 101120969 A CN101120969 A CN 101120969A
- Authority
- CN
- China
- Prior art keywords
- medicine
- group
- chinese medicine
- caulis spatholobi
- potentillae discoloris
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a medicine treating the diabetes and the complication as well as the preparation method. The medicine comprises the berberidis, the potentially discolour and the called millennial. The compatibility weight composition of the medicine comprises 20g to 50g berberidis, 20g to 50g potentillae discoloris and 20g to 60g caulis millettiae. The medicine of the present invention can be prepared by water extraction method with or without the alcohol extraction method. Compared with the present synthetic drug, the present invention has advantages of excellent safety property. Compared with the present Chinese herb, the present invention has properties of significant effect in reducing blood sugar level and preventing the complication of diabetes. The present invention can be produced as various kinds of proper preparation type for clinical application.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of diabetes and complication thereof and preparation method thereof, belong to the Chinese herbal and crude drugs preparations technical field.
Background technology
Diabetes are a kind of incretion metabolism diseases, increase with pathoglycemia, and metabolism disorder such as sugar, fat, protein and chronic progressive external nerve, vascular lesion are feature.Its case fatality rate is only second to cancer, coronary heart disease, hypertension, has become one of main public health problem that the whole world faces jointly.
Long-term hyperglycemia state can cause a series of chronic complicating diseases, mainly comprises trunk complication and microvascular complication.Common clinically diabetic complication has: diabetic coronary artery disease, diabetic retinopathy, diabetic nephropathy, the infection that diabetic peripheral neuropathy and diabetes cause etc.
Clinically, the conventional therapy of diabetic complication carries out symptomatic treatment based on blood sugar control at different diabetic complication clinical manifestations, medicine commonly used has medicament for expanding vascellum, vitamin medicaments, antibiotics, blood fat reducing and improve hemorheology medicine etc.Aldose reductase (AR) inhibitor, albumen nonenzymatic glycosylation blocker are another kind of diabetic complication medicines
A series of studies show that motherland's traditional medicine is carried out aspect the type 2 diabetes mellitus in treatment, the traditional Chinese medical science is being improved clinical symptoms, control complication, is being improved and therapeutical effect is preferably all arranged aspect patients ' life quality and the survival rate type 2 diabetes mellitus.Discover terpenoid, flavonoid, polysaccharide, polypeptide in the natural medicinal plant, compositions such as aminoacid, unsaturated fatty acid, alkaloid, steroidal and sulfide linkage chemical compound all have certain hypoglycemic activity.
Summary of the invention
Technical problem to be solved by this invention is: provide with brand-new component, form simple, therapeutic effect is good, the diabetes of efficacy stability and the compound medicine of complication thereof; Its scientific and reasonable, simple preparation method is provided simultaneously.
The medicine of treatment diabetes of the present invention and complication thereof, its compatibility of drugs weight consists of:
Radix Berberidis 20-50 part, Herba Potentillae Discoloris 20-50 part, Caulis Spatholobi 20-60 part.
Its percentage by weight is formed preferred:
Radix Berberidis 20g, Herba Potentillae Discoloris 30g, Caulis Spatholobi 20g;
Perhaps:
Radix Berberidis 25g, Herba Potentillae Discoloris 30g, Caulis Spatholobi 45g;
Perhaps:
Radix Berberidis 40g, Herba Potentillae Discoloris 20g, Caulis Spatholobi 30g
Described medicine is oral drugs, can be various clinical suitable dosage forms such as powder (can dress up capsule), pill, tablet, oral liquid.Preparation method is continued to use traditional Chinese medicinal preparation method and also can be effective, and the composition that obtains such as the method that adopts water extract-alcohol precipitation has effect too.
Summary of the invention
The present invention is noted that this compound recipe is carrying out zoopery, proves that this compound recipe has the effect of anti-diabetic and complication thereof.Extract with this compound recipe is used for pharmaceutical preparation simultaneously, obtains being suitable for the dosage form of clinical practice.
The present invention obtains the extract of this compound recipe by the following method:
Water extraction: get this compound medicine, extracting in water, merge extractive liquid, is concentrated into the extractum that every 1ml contains the 1g crude drug, promptly.The temperature of extracting is from 0～100 ℃.
Alcohol extracting method: get this compound medicine, add the lower alcohol alcohol extraction, merge extractive liquid, is concentrated into the extractum that every 1ml contains the 1g crude drug, promptly.Determining alcohol is from 30%～95%, and temperature is from 0～90 ℃.
Described lower alcohol comprises a kind of, perhaps two or more mixture of methanol, ethanol, normal propyl alcohol, isopropyl alcohol, n-butyl alcohol, isobutanol etc.
But each extract or the composition more than a certain class of the compound extract compound recipe that obtains with said method.
The present invention by to this compound extract in the research aspect blood sugar lowering and the diabetic complication, be the clinical drug regimen that a kind of blood sugar lowering safely and effectively and prevent diabetes complication are provided.Compare with existing synthetic drug, have safe advantage, compare with existing Chinese medicine and have hypoglycemic activity and control diabetic complication curative effect tangible characteristics, can make various suitable dosage forms clinically.
Description of drawings:
Figure of description 1:RM6420 bio signal acquisition processing system is measured rat tail motor nerve conduction velocity result;
Figure of description 2: diabetes rat slitting of lens lamp observed result.
The specific embodiment
Embodiment 1.
The traditional Chinese compound medicine of described treatment diabetes of present embodiment and complication disease thereof, its compatibility of drugs percentage by weight is:
Radix Berberidis 20g, Herba Potentillae Discoloris 30g, Caulis Spatholobi 20g.
Preparation method:
Add the water standing over night in the flask with being positioned over after the raw material pulverizing, water decocts three times, and the time was respectively 1 hour, 1 hour, 40 minutes, and water consumption is respectively 12 times, and 10 times, 10 times of volumes.Merge decoction liquor, the after-filtration that spends the night, the filtrate that obtains is concentrated into the extractum of 1mg/ml, is used for the animal experiment to the influence of blood glucose in diabetic mice.Pharmacological testing is reported as follows:
Chinese medicine compound is to the influence of blood glucose in diabetic mice
Kunming mouse, male, body weight 25-30g freely drinks water in the process of the test.After the mice fasting 16 hours, press 60mg/kg tail vein injection alloxan, after three days, eye socket is got the blood glucose of hematometry mice, elects fasting glucose 〉=12mmol/L person as diabetic mice.This compound recipe is divided into three dosage (high, medium and low) gives the alloxan mouse stomach, the compound recipe low dose group is pressed the 200mg/kg administration, middle dosage group is pressed the 400mg/kg administration, high dose group is pressed the 800mg/kg administration, model group and positive controls are irritated stomach by 10mL/kg respectively and are given distilled water and metformin (500mg/kg), continuous irrigation stomach seven days, last administration fasting in preceding four hours, two hours after administration socket of the eye vein is got hematometry mouse blood sugar value.
According to above experimental result, Chinese medicine compound is to the blood sugar reducing function of diabetic mice, and its result is as follows:
Tab：Effect of BSS on blood glucose in experimental mice
| Group | N | Dosage (mg/kg) | Blood glucose (mmol/L) before the administration | Blood glucose after the administration (mmol/L) |
| Model group | 11 | - | 25.58±5.05 | 20.76±5.58 |
| Metformin | 10 | 500 | 25.59±3.98 | 8.12±3.54 **## |
| Chinese medicine compound | 10 | 200 | 25.45±4.74 | 15.16±5.17 *## |
| 10 | 400 | 25.54±4.73 | 12.79±6.54 **## | |
| 10 | 800 | 25.75±4.36 | 9.14±7.60 **## |
Vs DM group
*p＜0.05
**p＜0.01
Vs control group
#p＜0.05
##p＜0.01
The result shows: this compound recipe can reduce the blood glucose of diabetic mice, and along with the rising of dosage, its hypoglycemic effect is also obvious more, and the state of administration group diabetic mice also has notable difference with the model group ratio.
Embodiment 2
The traditional Chinese compound medicine of described treatment diabetes of present embodiment and complication disease thereof, its compatibility of drugs percentage by weight is:
Radix Berberidis 25g, Herba Potentillae Discoloris 30g, Caulis Spatholobi 45g.
Preparation method:
Add 50% ethanol standing over night in the flask with being positioned over after the raw material pulverizing, heating and refluxing extraction 3 times, the time was respectively 1 hour, 1 hour, 40 minutes.Merge extractive liquid,, decompression recycling ethanol are used for the treatment of diabetes rat and complication thereof and the animal experiment of preventive effect to the extractum of 1mg/ml.Pharmacological testing is reported as follows:
Chinese medicine compound is to the treatment and the preventive effect of diabetes rat and complication thereof
The foundation of diabetes rat model: select the Wister rat that grows up for use, body weight 200-250g, male and female half and half are freely drunk water in the experimentation.After the rat fasting 16 hours, streptozotocin (preparation of 0.1mmol/l citrate buffer solution, pH=4.2) 52mg/kg disposable celiac injection.After 7 days, the socket of the eye vein is got blood and is surveyed blood glucose, elects fasting glucose 〉=16mmol/L person as diabetic mice.
Selected diabetes rat evenly is divided into 5 groups by blood glucose value and body weight, and free diet is raised and is pressed following administering mode administration after one month, and first group is diabetic model group, irritates stomach by 10mL/kg and gives distilled water; Second group is the Chinese medicine compound low dose group, irritates stomach by 150mg/kg and gives Chinese medicine compound solution; The 3rd group is dosage group in the Chinese medicine compound, irritates stomach by 300mg/kg and gives Chinese medicine compound solution, and the 4th group is the Chinese medicine compound high dose group, irritates stomach by 600mg/kg and gives Chinese medicine compound solution; The 5th group is TANGMAIKANG KELI (TMK) group, irritates stomach by 500mg/kg and gives TMK granule.And organize in contrast with the normal rat that body weight, Mus are complementary age, irritate stomach by 10mL/kg and give distilled water.Per 4 weeks are measured an index of correlation.
1 this compound recipe is to the influence of diabetes rat food-intake, amount of drinking water, voided volume and feces volume
Tab.1 Effect of CPM on food，water intake、urine volume and excrement weight inexperimental rats
| Group | Dose (mg/kg) | Food intake (g/d/unit weight) | Water intake (g/d/unit weight) | urine volume (g/d/unit weight) | Excrement (g/d/unit weight) |
| Control | - | 0.06±0.01 | 0.14±0.03 | 0.04±0.01 | 0.04±0.01 |
| DM | - | 0.18±0.07 ## | 0.87±0.23 ## | 0.71±0.16 ## | 0.28±0.05 ## |
| CPM | 400 | 0.14±0.04 *## | 0.51±0.10 **## | 0.39±0.09 **## | 0.16±0.04 **## |
| CPM | 200 | 0.19±0.05 ## | 0.73±0.17 ## | 0.64±0.15 ## | 0.20±0.04 **## |
| CPM | 100 | 0.18±0.06 ## | 072±0.20 ## | 0.60±0.09 ## | 0.18±0.03 **## |
| Metfor min | 200 | 0.14±0.04 *## | 0.48±0.15 ## | 0.53±0.18 **## | 0.19±0.09 **## |
#P＜0.05，
##P＜0.01vs control group；
*P＜0.05，
**P＜0.01vs DM group
By table as seen, diabetes rat food-intake, amount of drinking water, urine amount and feces volume all have significant increase (P＜0.01) than normal matched group, present " three-many-one-little " symptom of diabetes.Give and the high, medium and low dosage treatment of Chinese medicine compound after three months, the symptom of diabetes rat " three-many-one-little " is significantly improved, and high dose can reduce diabetes rat food-intake, amount of drinking water, urine amount and feces volume (P＜0.01) significantly.The impartial significant feces volume (P＜0.01) that reduces diabetes rat of middle dosage and low dosage can improve diabetes rat food-intake, amount of drinking water, urine amount.
2 Chinese medicine compound are to the influence of blood glucose in diabetic rats
Tab.2 Effect of CPM on glucose in experimental STZ rats
| Group | Dose (mg/kg) | Blood glucose(mmol/L) | |||
| After STZ | First month after administration | Second month after administration | Third month after administration | ||
| Control | - | 6.15±0.64 | 5.97±0.59 | 6.88±0.96 | 6.31±0.77 |
| DM | - | 21.27±4.63 ## | 27.82±3.39 ## | 24.33±3.53 ## | 27.12±2.48 ## |
| CPM | 400 | 21.05±4.23 ## | 12.11±5.70 **## | 9.01±3.52 ** | 8.31±1.58 **## |
| CPM | 200 | 20.92±3.86 ## | 16.24±6.23 **## | 1611±5.22 **## | 14.59±5.20 **## |
| CPM | 100 | 20.82±3.78 ## | 15.90±6.13 **## | 14.29±3.63 **## | 19.23±2.40 **## |
| Metformin | 200 | 21.26±3.44 ## | 9.34±3.60 **## | 11.33±4.68 **# | 13.90±4.87 **## |
#P＜0.05，
##P＜0.01 vs control group；
*P＜0.05，
**P＜0.01 vs DM group
By table as seen, the normal matched group fasting blood sugar of diabetes rat significantly raises (P＜0.01), and to after the high, medium and low dosage treatment of Chinese medicine compound, the diabetes rat fasting glucose significantly reduces, and blood sugar reducing function is steady, and is lasting.
3 Chinese medicine compound are to the influence of diabetes rat serum glycated protein (GSP)
Tab.3 Effect of CPM on GSP in experimental STZ rats
| Group | Dose (mg/kg) | Blood GSP(mmol/L) | ||
| First month after administration | Second month after administration | Third month after administration | ||
| Control | - | 1.13±0.19 | 1.20±0.10 | 1.01±0.07. |
| DM | - | 1.86±0.19 ## | 2.14±0.10 ## | 1.81±0.13 ## |
| CPM | 400 | 1.39±0.01 **# | 1.55±0.16 **## | 1.18±0.09 **## |
| CPM | 200 | 1.70±0.14 *## | 1.81±0.14 **## | 1.38±0.12 **## |
| CPM | 100 | 1.65±0.29 ## | 1.89±0.15 **## | 1.44±0.03 **## |
| Metformin | 200 | 1.42±0.15 **## | 1.64±0.25 **## | 1.36±0.11 **## |
#P＜0.05，
##P＜0.01 vs control group；
*P＜0.05，
**P＜0.01 vs DM group
By table as seen, the normal matched group saccharifying serum albumin of diabetes rat significantly raise (P＜0.01), after giving the high, medium and low dosage treatment of Chinese medicine compound, diabetes rat saccharifying serum albumin content obviously reduces (P＜0.01), the prompting Chinese medicine compound can be good at the fluctuation of blood sugar control, and can be good at suppressing the nonenzymatic glycosylation reaction of serum albumin.
4 Chinese medicine compound are to the influence of diabetes rat disorders of lipid metabolism and vascular lesion
4.1 Chinese medicine compound is to the influence of diabetes rat T-CHOL (CHO)
Tab.4 Effect of CPM on CHO in experimental STZ rats
| Group | Dose (mg/kg) | Blood CHO(mg/dL\ | ||
| First month after administration | Second month after administration | Third month after administration | ||
| Control | - | 50.08±10.05 | 42.29±7.84 | 43.87±5.56 |
| DM | - | 61.37±7.33 # | 79.03±14.77 ## | 85.00±14.52 ## |
| CPM | 400 | 55.24±13.81 | 60.06±17.77 *# | 60.26±13.91 **## |
| CPM | 200 | 64.25±8.82 # | 66.67±9.91 *## | 69.75±12.67 *## |
| CPM | 100 | 60.17±7.15 # | 79.74±13.08 ## | 84.28±6.26 ## |
| Metformin | 200 | 61.04±10.66 | 58.96±11.84 **## | 66.98±11.30 **## |
#P＜0.05，
##P＜0.01 vs control group；
*P＜0.05，
**P＜0.01 vs DM group
By table as seen, the normal matched group of diabetes rat total cholesterol level has significant rising (P＜0.01), after giving the high, medium and low dosage treatment of Chinese medicine compound, total cholesterol level has significant difference than model control group in the compound recipe high dose group animal serum, and the dosage group can obviously reduce serum total cholesterol content (P＜0.01) in the compound recipe.
4.2 Chinese medicine compound is to the influence of diabetes rat triglyceride (TG)
Tab.5Effect of CPM on TG in experimental STZ rats
| Group | Dose (mg/kg) | Blood TG(mg/dL) | ||
| First month after administration | Second month after administration | Third month after administration | ||
| Control | - | 68.38±26.54 | 40.59±14.13 | 36.64±5.11 |
| DM | - | 107.76±20.58 ## | 125.17±41.02 ## | 125.64±15.23 ## |
| CPM | 400 | 55.20±32.29 ** | 59.03±17.47 **# | 57.29±12.88 **## |
| CPM | 200 | 101.24±41.88 | 93.16±21.79 *## | 84.31±15.72 **## |
| CPM | 100 | 103.04±36.29 | 93.89±11.48 ## | 102.28±16.04 **## |
| Metformin | 200 | 100.82±30.83 # | 59.51±21.82 **# | 67.24±19.88 **## |
#P＜0.05，
##P＜0.01 vs control group；
*P＜0.05，
**P＜0.01 vs DM group
By table as seen, the normal matched group of diabetes rat content of triglyceride has significant rising (P＜0.01), after giving the high, medium and low dosage treatment of Chinese medicine compound, total content of triglyceride has significant reduction (P＜0.01) than model control group in the diabetes rat serum, and the prompting compound medicine can improve the disorder of diabetes rat lipid metabolism to a certain extent.
4.3 Chinese medicine compound is to the influence of diabetes rat high density lipoprotein (HDL-C)
Tab.6 Effect of complex prescription metformin on HDL in experimental STZ rats
| Group | Dose (mg/kg) | Blood HDL(mg/dL) | ||
| First month after administration | Second month after administration | Third month after administration | ||
| Control | - | 81.44±14.20 | 84.52±15.46 | 79.92±13.93 |
| DM | - | 48.98±7.54 ## | 45.98±6.46 ## | 39.83±5.08 ## |
| CPM | 400 | 68.21±13.58 **# | 70.83±14.43 ** | 78.51±12.00 ** |
| CPM | 200 | 58.25±10.56 *## | 59.82±13.11 *## | 54.27±7.95 **## |
| CPM | 100 | 60.97±7.51 *## | 58.57±8.22 *## | 44.44±5.64 ## |
| Metformin | 200 | 62.09±12.02 **## | 64.01±8.43 **## | 58.68±12.55 **## |
#P＜0.05，
##P＜0.01vs control group；
*P＜0.05，
**P＜0.01vs DM group
By table as seen, the normal matched group of diabetes rat hdl concentration has significant reduction (P＜0.01).After giving the high, medium and low dosage treatment of Chinese medicine compound, high, middle dosage and metformin group hdl concentration have had significant rising (P＜0.01).The prompting compound medicine can effectively improve the content of diabetic animal serum high-density LP.
4.4 Chinese medicine compound is to the influence of diabetes rat low density lipoprotein, LDL (LDL-C)
Tab.7Effect of CPM on LDL-C in experimental STZ rats
| Group | Dose (mg/kg) | Blood LDL-C(mg/dL) | ||
| First month after administration | Second month after administration | Third month after administration | ||
| Control | - | 27.54±7.31 | 29.76±9.86 | 30.59±9.65 |
| DM | - | 62.66±12.03 ## | 64.57±11.08 ## | 70.91±12.91 ## |
| CPM | 400 | 37.31±8.25 **## | 36.74±10.33 **## | 34.85±9.76 **## |
| CPM | 200 | 45.20±13.02 *## | 44.65±12.97 *## | 50.73±13.46 *## |
| CPM | 100 | 65.91±11.06 ## | 63.26±14.20 ## | 66.06±12.73 ## |
| Metformin | 200 | 43.03±10.79 **## | 40.31±10.29 **## | 45.97±13.21 *## |
#P＜0.05，
##P＜0.01vs control group；
*P＜0.05，
**P＜0.01vs DM group
By table as seen, the normal matched group of diabetes rat LDL-C content has significant rising (P＜0.01), after giving the high, medium and low dosage treatment of Chinese medicine compound, LDL-C content has significant reduction (P＜0.01) than model control group in the diabetes rat serum, the prompting Chinese medicine compound can reduce the content of serum LDL-C, and disorders of lipid metabolism is had some improvement.
5 Chinese medicine compound are to the influence of diabetes rat coccygeal nerve conduction
5.1 the mensuration of rat coccygeal nerve conduction velocity
Use RM6420 bio signal acquisition processing system and measure rat tail motor nerve conduction velocity, measurement result is referring to Figure of description 1, shown in the table 8:
Tab.8 Effect of CPM on nerve conduction velocity in experimental STZ rats
| Group | Dose(mg/kg) | Nerve conduction velocity (m/s) |
| Control | - | 18.92±1.97 |
| DM | - | 12.19±0.69 ## |
| CPM | 400 | 15.52±1.59 **## |
| CPM | 200 | 15.16±1.15 **## |
| CPM | 100 | 13.41±1.32 *## |
| Metformin | 200 | 15.26±1.49 **## |
#P＜0.05，
##P＜0.01vs control group；
*P＜0.05，
**P＜0.01vs DM group
By table as seen, the coccygeal nerve conduction velocity of course of disease diabetes rat after three months has been starkly lower than normal control group (P＜0.01).Give the high, medium and low dosage treatment of Chinese medicine compound after three months, the nerve conduction velocity of administration group rat all significantly speeds (P＜0.01) than diabetic model group, but with the normal control group tangible difference (P＜0.01) is arranged more still.
5.2 Chinese medicine compound is to the influence of the diabetes rat pain sensation
Tab.9 Effect of CPM on tail withdraw reflex caused by thermal stimulation in experimental STZrats
| Group | Dose (mg/kg ) | tail withdraw reflex caused by thermal stimulation (Second) | ||
| First month after administration | Second month after administration | Third month after administration | ||
| Control | - | 4.20±0.42 | 4.24±0.71 | 3.94±0.51 |
| DM | - | 5.47±0.81 ## | 5.62±0.78 ## | 5.78±0.47 ## |
| CPM | 400 | 4.54±0.91 * | 4.20±0.59 ** | 4.70±0.77 **# |
| CPM | 200 | 5.14±1.51 # | 4.74±0.94 * | 4.83±0.84 *# |
| CPM | 100 | 5.21±0.53 ## | 5.18±0.50 # | 6.08±0.34 ## |
| Metformin | 200 | 4.71±0.63 *# | 4.79±0.81 ** | 4.97±0.77 *# |
#P＜0.05，
##P＜0.01vs control group
*P＜0.05，
**P＜0.01vs DM group
By table as seen, the pain sensation normal matched group incubation period of diabetes rat obviously prolongs (P＜0.01), the phenomenon blunt to burning pain occur.Give the high, medium and low dosage treatment of Chinese medicine compound after three months, the diabetes rat pain sensation has had tangible shortening (P＜0.01) incubation period, but normal matched group also has difference (P＜0.01).
6 Chinese medicine compound are to the relevant index determining with kidney disease of diabetes rat
6.1 Chinese medicine compound is to the influence of diabetes rat plasma urea nitrogen
Tab.10：Effect of BSS on the content of LDH in experimental rats
| Group | Dose(mg/kg) | BUN(mmol/L) | ||
| The fifth week | The ninth week | The thirteenth week | ||
| DM | - | 13.79±1.29## | 11.22±0.78## | 15.38±1.05## |
| TMK | 500 | 12.97±5.08## | 11.91±1.26## | 8.8±0.94## ** |
| BSS | 150 | 14.75±2.85## | 10.5±1.7## | 11.94±1.84## * |
| 300 | 15.61±5.15## | 9.78±1.39## * | 11.97±1.63## ** | |
| 600 | 17.6±4.9## | 9.10±1.27## ** | 9.78±1.44## ** | |
| Control | - | 6.25±3.86 ** | 6.06±1.56 ** | 5.64±1.94 ** |
Vs DM group
*p＜0.05
**p＜0.01 Vs control group#p＜0.05## p＜0.01
It is as shown in the table for the result, gives Chinese medicine compound three dosage groups three months, and diabetes rat plasma urea nitrogen content obviously descends, and the prompting Chinese medicine compound has the effect that reduces diabetes rat plasma urea nitrogen content preferably.
6.2 Chinese medicine compound is to the influence of diabetes rat urine protein content
Tab.11：Effect of BSS on the content of Urine protein in experimental rats
| Group | Dose(mg/kg) | Urine protein(mg/dL) |
| DM | - | 6.25±2.50 ## |
| TMK | 500 | 0.00±0.00 ** |
| BSS | 150 | 1.67±2.58 *## |
| 300 | 0.71±1.89 **## | |
| 600 | 0.00±0.00 ** | |
| Control | - | 0.00±0.00 ** |
Vs DM group
*p＜0.05
**p＜0.01
Vs control group
#p＜0.05
##p＜0.01
It is as shown in the table for the result, gives Chinese medicine compound three dosage groups three months, and the diabetes rat urine protein content obviously descends, and the prompting Chinese medicine compound has the effect that reduces the diabetes rat urine protein content preferably.
7 Chinese medicine compound are to the influence of diabetes rat lenticular opacity
Tab 12.Effect of BSS on lenticular opacity in experimental rats(x±s)
| Group | Dose(mg/kg) | N | Number of lenticular opacity | Rate of opacity (100％) |
| DM | - | 5 | 3 | 60.0 |
| TMK | 500 | 5 | 1 | 20.0 |
| BSS | 150 | 7 | 2 | 28.6 |
| 300 | 7 | 1 | 14.3 | |
| 600 | 9 | 2 | 22.2 | |
| Control | - | 10 | 0 | 0.0 |
It is as shown in the table for the result, and diabetes rat lenticular opacity rate raises, and TMK group and Chinese medicine compound group lenticular opacity rate are low than the model group rat, and blank group rat is not found the situation of lenticular opacity.The prompting Chinese medicine compound can reduce diabetes rat lenticular opacity rate, may have to reduce the effect that diabetic cataract takes place.Pharmacological tests is referring to Figure of description 2.
Claims (12)
1. a Chinese medicine composition that is used for the treatment of diabetes and complication thereof is characterized in that the raw material composition of this Chinese medicine composition comprises following three kinds of compositions at least: Radix Berberidis, Herba Potentillae Discoloris, Caulis Spatholobi.
2. Chinese medicine composition according to claim 1 is characterized in that it is to be made by the crude drug of following weight portion ratio: Radix Berberidis 10-50 part, Herba Potentillae Discoloris 10-50 part, Caulis Spatholobi 10-60 part.
3. Chinese medicine composition according to claim 2, it is characterized in that its crude drug part by weight scope can be: Radix Berberidis 20-40g, Herba Potentillae Discoloris 20-40g, Caulis Spatholobi are 20-45g.
4. medicine according to claim 2 is characterized in that its crude drug part by weight can be: Radix Berberidis 20g, Herba Potentillae Discoloris 30g, Caulis Spatholobi 20g.
5. medicine according to claim 2 is characterized in that its crude drug part by weight can be: Radix Berberidis 25g, Herba Potentillae Discoloris 30g, Caulis Spatholobi 45g.
6. medicine according to claim 2 is characterized in that its crude drug part by weight can be: Radix Berberidis 40g, Herba Potentillae Discoloris 20g, Caulis Spatholobi 30g.
7. according to the arbitrary described medicine of claim 1-6, it is characterized in that this medicine is powder, capsule, tablet, pill or oral liquid.
8. according to the described medicine of claim 7, it is characterized in that its preparation method can be that water is as solvent, with the effective site in conventional method extraction Herba Potentillae Discoloris, Folium Psidii Guajavae, the Caulis Spatholobi, and formulation method is made powder, capsule, tablet, pill, oral liquid and other oral formulations forms routinely.
9. the extracting method of described medicine according to Claim 8, the temperature that it is characterized in that extracting is between 0～100 ℃.
10. according to right medicine 7 described medicines: it is characterized in that its preparation method can be as solvent with lower alcohol, with the effective site in conventional method extraction Herba Potentillae Discoloris, Folium Psidii Guajavae, the Caulis Spatholobi, and formulation method is made powder, capsule, tablet, pill, oral liquid and other oral formulations forms routinely.
11. according to the extracting method of the described medicine of claim 10, its lower alcohol as solvent comprises a kind of of methanol, ethanol, normal propyl alcohol, isopropyl alcohol, n-butyl alcohol, isobutanol etc., perhaps any two or more mixture.
12. according to the extracting method of the described medicine of claim 10, it is characterized in that the determining alcohol that extracts is between 30%～95%, temperature is between 0～90 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006101043298A CN101120969A (en) | 2006-08-08 | 2006-08-08 | Medicine for treating diabetes and its complications and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006101043298A CN101120969A (en) | 2006-08-08 | 2006-08-08 | Medicine for treating diabetes and its complications and preparing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101120969A true CN101120969A (en) | 2008-02-13 |
Family
ID=39083607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006101043298A Pending CN101120969A (en) | 2006-08-08 | 2006-08-08 | Medicine for treating diabetes and its complications and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101120969A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102217686A (en) * | 2011-06-02 | 2011-10-19 | 王乃利 | Hypoglycemic tea and preparation method thereof |
| CN101249129B (en) * | 2008-03-31 | 2011-11-16 | 周小江 | Chinese medicine extract combination and medicine use thereof |
| CN109411032A (en) * | 2017-10-18 | 2019-03-01 | 中粮营养健康研究院有限公司 | The functional component appraisal procedure and machine readable storage medium of edible medicinal plant |
-
2006
- 2006-08-08 CN CNA2006101043298A patent/CN101120969A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249129B (en) * | 2008-03-31 | 2011-11-16 | 周小江 | Chinese medicine extract combination and medicine use thereof |
| CN102217686A (en) * | 2011-06-02 | 2011-10-19 | 王乃利 | Hypoglycemic tea and preparation method thereof |
| CN109411032A (en) * | 2017-10-18 | 2019-03-01 | 中粮营养健康研究院有限公司 | The functional component appraisal procedure and machine readable storage medium of edible medicinal plant |
| CN109411032B (en) * | 2017-10-18 | 2021-08-17 | 中粮营养健康研究院有限公司 | Method for evaluating functional components of edible and medicinal plants and machine-readable storage medium |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041118B (en) | Composition with effects of reducing blood sugar and reducing blood lipid | |
| CN100998650A (en) | Use of cinnamonum cassia for treating diabetes, its products and preparing method | |
| CN105920067A (en) | Sunflower calathide extract containing polysaccharide, flavonoid and alkaloid and preparation method of sunflower calathide extract | |
| CN1899342A (en) | Oral medicine for treating diabetes and its use | |
| CN1965873B (en) | Chinese medicinal extract having blood sugar-lowering activity, its preparation process, composition and use | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN101810636B (en) | Application of Chinese yam polysaccharide in preparation of medicament for treating obesity | |
| CN109125315A (en) | Composition and purposes with hypoglycemic, reducing blood lipid and hypotensive activity | |
| CN1329049C (en) | Blood sugar- and blood pressure-lowering medicine | |
| CN101120969A (en) | Medicine for treating diabetes and its complications and preparing method thereof | |
| CN100534461C (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and preparation method thereof | |
| CN114272295B (en) | Traditional Chinese medicine composition for treating diabetic acromelic gangrene | |
| CN100579564C (en) | Medicine for curing gout and its preparing method | |
| CN101491668B (en) | Composition with blood-sugar reducing function and preparation method thereof | |
| CN103432420A (en) | Traditional Chinese medicine composition for treating diabetes, and preparation method and detection method thereof | |
| CN105055851A (en) | Chinese medicinal composition for treatment of diabetes, preparation and application thereof | |
| CN101406576B (en) | Chinese medicine for treating diabetes and preparation method | |
| CN112022981A (en) | Traditional Chinese medicine increasing and decreasing formula for preventing/treating metabolic syndrome and complications thereof | |
| CN109010621A (en) | A kind of Chinese medicine composition that treating diabetes, preparation method and applications | |
| CN103721074B (en) | Pharmaceutical composition and preparation method and application thereof | |
| CN102631486B (en) | Health care composition | |
| CN102631506B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN107213204B (en) | Traditional Chinese medicine compound preparation for treating diabetes and preparation method and application thereof | |
| CN105796615A (en) | Moringa oleifera effective ingredient capable of relieving intestinal injury and preparation method and application thereof | |
| CN101491581A (en) | Combination with blood sugar reducing function and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20080213 |